Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Ranibizumab 0.5 mg Monthly	275
Overall Study	STARTED	Ranibizumab 2.0 mg Monthly	274
Overall Study	STARTED	Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])	275
Overall Study	STARTED	Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])	273
Overall Study	COMPLETED	Ranibizumab 0.5 mg Monthly	258
Overall Study	COMPLETED	Ranibizumab 2.0 mg Monthly	258
Overall Study	COMPLETED	Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])	263
Overall Study	COMPLETED	Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])	258
Overall Study	NOT COMPLETED	Ranibizumab 0.5 mg Monthly	17
Overall Study	NOT COMPLETED	Ranibizumab 2.0 mg Monthly	16
Overall Study	NOT COMPLETED	Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])	12
Overall Study	NOT COMPLETED	Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])	15

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00891735/flow